RxDoctor Payments Data

Leela Raju, MD

Ophthalmology · New York, NYNPI 1972705069

Payments from drug & device makers

$19,271in general payments, 2019–2025

Across 99 payments — averaging $194.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Carl Zeiss Meditec, Inc.$6K
  • Johnson & Johnson Surgical Vision, Inc.$3K
  • AbbVie$2K
  • PTC Therapeutics, Inc.$2K
  • Alcon$2K
  • NEW World Medical,inc.$813
  • plus $3K from 17 others

What the payments were for

  • Consulting fees$12,47565%
  • Speaking & faculty fees$7004%
  • Travel & lodging$4162%
  • Food & beverage$5,68029%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,271 in reported general payments places this provider in the 90th percentile of 1,587 ophthalmology providers in New York.

See all ophthalmology providers in New York

Medicare billing

Part B allowed, 2024
$35,776
Medicare patients
143
Services billed
285

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine75$54,081
LumiganBimatoprost56$21,442
XiidraLifitegrast12$12,290
Travoprost48$10,881
CombiganBrimonidine Tartrate/Timolol11$5,930
SimbrinzaBrinzolamide/Brimonidine Tart24$5,928
Cyclosporine13$4,938
Brimonidine Tartrate44$3,627
Latanoprost324$3,385
Prednisolone Acetate42$1,504
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat87$1,468
Timolol Maleate69$809
ValacyclovirValacyclovir Hcl20$701
Azelastine Hcl14$356
Ketorolac Tromethamine19$303

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$2,054$81,454142 claims
Bausch & Lomb Americas Inc.Xiidra$315$12,29012 claims
AlconSimbrinza$2,019$5,92824 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,587 ophthalmology providers in New York.

Other ophthalmology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →